ISRAEL 
HIGH-TECH & INVESTMENT REPORT

from the October 2005 issue


Kamada Obtains Order for Transferrin


Rehovot-based Kamada (TASE:KMDA) announced its first order, for about $225,000, for its Transferrin protein. The customer will be using the transferrin in advanced clinical trials of a cancer drug. Transferrin is a protein naturally found in the plasma, that transfers iron through the bloodstream to the organs, such as the liver and bone marrow. Cancer is one condition that can depress transferrin levels in the blood, leading to anemia.

The company has pointed to studies indicating that transferrin might be useful in transporting drugs as well, especially to cancer cells. The tighter the focus on drug transport, the more efficient and the less destructive therapy can be.

Kamada manager David Tzur commented that the company is in preliminary stages of adapting the process of transferrin production for use in humans and in drugs.

Kamada recently floated on the Tel Aviv Stock Exchange, raising $7.0m. at a company value of $19m. and has recently completed a $3.4 million private placement led by Leon Recanati's GlenRock Fund.


Reprinted from the Israel High-Tech & Investment Report October 2005

Click HERE to request further information.
Click HERE to go BACK.